PSA Kinetics as Prognostic Markers of Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate

BACKGROUND: Abiraterone acetate (AA) is widely used in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). However, a significant percentage of patients will still progress, highlighting the need to identify patients more likely to benefit from AA. Parameters link...

Descripción completa

Detalles Bibliográficos
Autores principales: España, Sofia, Ochoa de Olza, Maria, Sala, Nuria, Piulats, Josep Maria, Ferrandiz, Ulises, Etxaniz, Olatz, Heras, Lucia, Buisan, Oscar, Pardo, Juan Carlos, Suarez, Jose F, Barretina, Pilar, Comet, Josep, Garcia del Muro, Xavier, Sumoy, Lauro, Font, Albert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584507/
https://www.ncbi.nlm.nih.gov/pubmed/33116879
http://dx.doi.org/10.2147/CMAR.S270392

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584507/
https://www.ncbi.nlm.nih.gov/pubmed/33116879
http://dx.doi.org/10.2147/CMAR.S270392

Ejemplares similares